WFA
KROS icon

Wipfli Financial Advisors’s Keros Therapeutics KROS Stock Holding History

Wipfli Financial Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1K Buy
+21
New +$728 ﹤0.01% 2437

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wipfli Financial Advisors's KROS Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Keros Therapeutics (KROS) in Q3 2022: 21 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2437 among its holdings.

113 funds tracked by Wall St. Rank hold KROS as of Q3 2022.

  • Wipfli Financial Advisors held 21 shares of Keros Therapeutics worth $1K as of Q3 2022.
  • Keros Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
  • Keros Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2437 holding.
  • 113 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.